Japanese biopharma company Sosei Group on Thursday bought Swiss-based Idorsia Pharmaceuticals’ operations in Japan and South Korea for about 65 billion yen ($466.1 million) in its largest acquisition to date.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
